- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
ENZN Market Currents
more »
-
February 28 Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon.
Comment![Healthcare]
ENZN Related Articles
more »
ENZN News
more »
-
at MarketWatch.com (Sep 23, 2011)
-
at CNBC.com (Aug 10, 2011)
-
at CNBC.com (Dec 15, 2010)
ENZN Press Releases and Filings
more »
-
Marketwire (May 7, 2012)
-
Marketwire (May 2, 2012)
-
Marketwire (Mar 12, 2012)
-
Marketwire (Dec 8, 2011)
ENZN Latest Transcript
more »
ENZN Cramer
more »
Currently, there are no Cramer articles on ENZN.
ENZN Instablog posts
more »
ENZN vs. ETF Alternatives
Company Description
We are a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. We have a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Our drug development... More
